U.S. pharma large copyright scrapped two experimental weight loss tablets final calendar year—a once-daily capsule, lotiglipron, due to elevated liver enzymes in addition to a 2 times-each day tablet, danuglipron, because of strong side effects—but CEO Albert Bourla has reported the